Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management
November 10th 2023Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer
November 10th 2023Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
Enfortumab Vedotin Plus Pembrolizumab Has Potential to Alter SOC in Frontline Urothelial Cancer
The combination of enfortumab vedotin-ejfv plus pembrolizumab represents a chemotherapy-free regimen that could alter the standard of care in the frontline treatment of all patients with metastatic urothelial carcinoma.
Dr Braun on the Clinical Implications of the CONTACT-03 Trial in RCC
November 10th 2023David Braun, MD, PhD, discusses the findings from the phase 3 CONTACT-03 trial investigating immunotherapy rechallenge in patients with renal cell carcinoma and the implications of these findings on the RCC treatment paradigm.
Dr Markman on Pragmatic Clinical Trial Designs in Ovarian Cancer
November 9th 2023Maurie Markman, MD, discusses the importance of designing clinical trials for patients with ovarian cancer that are based on real-world data and consider the increasing complexity of treatment sequencing in this disease.
Markman Underscores Unanswered Questions in Ovarian Cancer Management
November 9th 2023Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.
Data Continue to Refine Frontline BTK Inhibitor Selection in CLL
Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.
PD-L1 Status Could Help Inform Patient Selection for IO-Based Therapy in HNSCC
December 15th 2022Ranee Mehra, MD, discusses the significance of 5-year follow-up data and the subgroup analysis from KEYNOTE-048, the benefits and limitations of IO therapy in head and neck squamous cell carcinoma, and research aiming to expand the role of IO combination regimens in this space.
Novel Targeted Immunotherapies Strengthen Frontline Treatment Strategies in Hodgkin Lymphoma
December 15th 2022Joshua Brody, MD, discusses unmet needs in patient subgroups within Hodgkin lymphoma, recent advancements in the use of antibody-drug conjugates such as brentuximab vedotin and anti–PD-1 therapies in earlier lines of therapy, and future avenues for expanding the use of immunotherapy in this tumor type.
Dr. Perl on Genetic Testing and Targeted Therapies in AML
November 10th 2022Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.
Every Patient With Metastatic Melanoma “Deserves a Shot at Nivolumab/Ipilimumab,” Weber Says
The combination of nivolumab and ipilimumab have shown overall survival benefit in patients with metastatic melanoma, according to long-term follow-up data, and other studies’ results highlight the efficacy and toxicity benefits of different sequences of the combination.
PARP Maintenance Therapy Provides Varying Benefit in Advanced Ovarian Cancer
The benefit of PARP maintenance therapy for patients with advanced ovarian cancer differs depending on a number of factors, including the homologous recombination and BRCA mutation status of the tumor.
Sequencing Strategies, Improving QOL Are Top Priorities in Neuroendocrine Neoplasm Treatment
November 10th 2022Diane Reidy-Lagunes, MD, discussed the role of next-generation sequencing paired with systemic therapies and the option of peptide receptor radionuclide therapy in neuroendocrine malignancies.
Breast Cancer Advances in 2022 Shape CFS Agenda
November 10th 2022Emerging novel therapies, new stratification factors, and sequencing challenges because of the new classifications for patients with breast cancer will be topics of discussion at the 40th Annual Chemotherapy Foundation Symposium® during the breast cancer sessions.